Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect

The availability of new potent systemic therapies for urothelial carcinoma may change the way we use standard chemotherapy perioperatively. In particular, identifying which patients with muscle-invasive bladder cancer (MIBC) would benefit from adjuvant chemotherapy (AC) is compelling. From a multice...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Eur Urol
Hlavní autoři: Pederzoli, Filippo, Bandini, Marco, Briganti, Alberto, Plimack, Elizabeth R., Niegisch, Günter, Yu, Evan Y., Bamias, Aristotelis, Agarwal, Neeraj, Sridhar, Srikala S., Sternberg, Cora N., Vaishampayan, Ulka N., Théodore, Christine, Rosenberg, Jonathan E., Harshman, Lauren C., Bellmunt, Joaquim, Galsky, Matthew D., Gallina, Andrea, Salonia, Andrea, Montorsi, Francesco, Necchi, Andrea
Médium: Artigo
Jazyk:Inglês
Vydáno: 2019
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6852645/
https://ncbi.nlm.nih.gov/pubmed/31303258
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eururo.2019.06.032
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky